Abstract & Authors:展开
Caloric restriction and intermittent fasting are known to prolong life- and healthspan in model organisms, while their effects on humans are less well studied. In a randomized controlled trial study (ClinicalTrials.gov identifier: NCT02673515), we show that 4 weeks of strict alternate day fasting (ADF) improved markers of general health in healthy, middle-aged humans while causing a 37% calorie reduction on average. No adverse effects occurred even after >6 months. ADF improved cardiovascular markers, reduced fat mass (particularly the trunk fat), improving the fat-to-lean ratio, and increased β-hydroxybutyrate, even on non-fasting days. On fasting days, the pro-aging amino-acid methionine, among others, was periodically depleted, while polyunsaturated fatty acids were elevated. We found reduced levels sICAM-1 (an age-associated inflammatory marker), low-density lipoprotein, and the metabolic regulator triiodothyronine after long-term ADF. These results shed light on the physiological impact of ADF and supports its safety. ADF could eventually become a clinically relevant intervention.
Slaven Stekovic,Sebastian J Hofer,Norbert Tripolt
Slaven Stekovic,Sebastian J Hofer,Norbert Tripolt,Miguel A Aon,Philipp Royer,Lukas Pein,Julia T Stadler,Tobias Pendl,Barbara Prietl,Jasmin Url,Sabrina Schroeder,Jelena Tadic,Tobias Eisenberg,Christoph Magnes,Michael Stumpe,Elmar Zuegner,Natalie Bordag,Regina Riedl,Albrecht Schmidt,Ewald Kolesnik,Nicolas Verheyen,Anna Springer,Tobias Madl,Frank Sinner,Rafael de Cabo,Guido Kroemer,Barbara Obermayer-Pietsch,Jöm Dengjel,Harald Sourij,Thomas R Pieber,Frank Madeo
Leonie K. Heilbronn, Satchidananda Panda，2019-09-03